Abstract
Background: The early diagnosis of sepsis plays a central role in patient management. Many mediators to be the cause of sepsis have been proposed. In the present study the combined measurement of procalcitonin (PCT) and mid-regional pro-adrenomedullin (MR-proADM) and their appropriate cut-off values in sepsis patients were evaluated.
Methods: PCT and MR-proADM were measured with commercially available immunoluminometric assays (Brahms, Hennigsdorf, Germany) in 200 septic patients, 90 patients with SIRS and 30 healthy individuals. Data were analyzed with ROC curve analysis and likelihood ratios with the MedCalc 11.6.1.0 package.
Results: Healthy controls and non-infectious SIRS were clearly distinguished from sepsis patients using the following cut-off values: 0.30 ng/mL for PCT and 1 nmol/L for ADM. In the 200 septic patients the areas under the curve (AUCs) for PCT and MR-proADM were 0.921 and 0.977, respectively, with a statistically significant difference between the two areas of 0.0563 (p=0.0002). Gram-positive, Gram-negative, yeast and polymicrobial sepsis patients showed different geometric means of the two biomarkers: this difference was relevant in Gram-positive sepsis and in yeast sepsis, 0.0819 (p=0.0076) and 0.188 (p=0.0062), respectively. The combined use of PCT and MR-proADM gave a post-test probability of 0.998 in the cohort of all septic patients. By test combination the post-test probability changed from 0.803 to 0.957 in Gram-positive sepsis and from 0.928 to 0.995 in yeast sepsis.
Conclusions: In conclusion, data from this study demonstrates that the combined use of PCT and MR-proADM, may substantially improve the early diagnosis of sepsis.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. American College of Chest Physicians/Society of Critical Care Medicine. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864–74.10.1097/00003246-199206000-00025Search in Google Scholar
2. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003;31:1250–6.10.1097/01.CCM.0000050454.01978.3BSearch in Google Scholar PubMed
3. Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. Br Med J 2007;335:879–83.10.1136/bmj.39346.495880.AESearch in Google Scholar PubMed PubMed Central
4. Paul M, Shani V, Muchtar E, Kariv G, Robenshto E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010;54:4851–63.10.1128/AAC.00627-10Search in Google Scholar PubMed PubMed Central
5. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG. The pathogenesis of sepsis. Annu Rev Pathol 2011;6:19–48.10.1146/annurev-pathol-011110-130327Search in Google Scholar PubMed PubMed Central
6. Heffner AC, Horton JM, Marchick MR, Jones AE. Etiology of illness in patients with severe sepsis admitted to the hospital from the emergency department. Clin Infect Dis 2010;50: 814–20.10.1086/650580Search in Google Scholar PubMed PubMed Central
7. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMP cause inflammatory response to injury. Nature 2010;464:104–7.10.1038/nature08780Search in Google Scholar PubMed PubMed Central
8. Castellheim A, Brekke OL, Espevik T, Harboe M, Mollness TE. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol 2009;69:479–91.10.1111/j.1365-3083.2009.02255.xSearch in Google Scholar PubMed
9. Lopez-Collazo E, Gomez-Pina V, Arnalich F. Understanding immune dysfunctions in sepsis patients. Crit Care 2010;14:435.10.1186/cc9202Search in Google Scholar PubMed PubMed Central
10. Anas AA, Wiersinga WJ, de Vos AF, van der Poll T. Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 2010;68:147–52.Search in Google Scholar
11. van der Poll T, Meijers JC. Systemic inflammatory response syndrome and compensatory anti-inflammatory response syndrome in sepsis. J Innate Immun 2010;2:379–80.10.1159/000318190Search in Google Scholar PubMed
12. Sheldon J, Riches P, Gooding R, Soni N, Hobbs JR. C-reactive protein and its cytokine mediators in intensive-care patients. Clin Chem 1993;39:147–50.10.1093/clinchem/39.1.147Search in Google Scholar
13. Carrigan SD, Scott G, Tabrizian M. Towards resolving the challenges of sepsis diagnosis. Clin Chem 2004;50:1301–14.10.1373/clinchem.2004.032144Search in Google Scholar
14. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007;11:R38.10.1186/cc5723Search in Google Scholar
15. de Kruif MD, Limper M, Gerritsen H, Spek CA, Brandjes DP, ten Cate H, et al. Additional value of procalcitonin for diagnosis of infection in patients with fever at the emergency department. Crit Care Med 2010;38:457–63.10.1097/CCM.0b013e3181b9ec33Search in Google Scholar
16. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206–17.10.1086/421997Search in Google Scholar
17. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohoun C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515–8.10.1016/0140-6736(93)90277-NSearch in Google Scholar
18. Gaini S, Koldkjaer OG, Moller HJ, Pedersen C, Pedersen SS. A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Crit Care 2007;11:R76.10.1186/cc5967Search in Google Scholar PubMed PubMed Central
19. Limper M, de Kruif MD, Duits AJ, Brandjes DP, van Gorp EC. The diagnostic role of procalcitonin and other biomarkers in discriminating infectious from non-infectious fever. J Infect 2010;60:409–16.10.1016/j.jinf.2010.03.016Search in Google Scholar PubMed
20. Gilbert DN. Use of plasma procalcitonin levels as an adjunct to clinical microbiology. J Clin Microbiol 2010;48:2325–9.10.1128/JCM.00655-10Search in Google Scholar PubMed PubMed Central
21. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target. Br J Pharmacol 2010;159:253–64.10.1111/j.1476-5381.2009.00433.xSearch in Google Scholar PubMed PubMed Central
22. Becker KL. Immunoneutralization of procalcitonin or its component peptides: a promising treatment of sepsis. Clin Sci 2010;119:515–7.10.1042/CS20100367Search in Google Scholar
23. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005;9:R816–24.10.1186/cc3885Search in Google Scholar
24. Zudaire E, Portal-Nunez S, Cuttitta F. The central role of adrenomedullin in host defense. J Leukoc Biol 2006;80:237–44.10.1189/jlb.0206123Search in Google Scholar
25. Hynson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000;21:138–67.Search in Google Scholar
26. Petti CA, Weinstein MP, Carroll KC. Systems for detection and identification of bacteria and yeast. In: Versalovic J, Carroll KC, Funke G, Joregnsen JH, landry ML, Warnock DW, editors. Manual of clinical microbiology. 10th ed. Washington: ASM Press, 2011.Search in Google Scholar
27. Caruhel P, Mazier C, Kunde J, Morgenthaler NG, Darbouret B. Homogeneous time-resolved fluoroimmuno assay for the measurement of mid-regional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. Clin Biochem 2009;42:725–8.10.1016/j.clinbiochem.2009.01.002Search in Google Scholar
28. Florkowski CM. Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. Clin Biochem Rev 2008;29:S83–7.Search in Google Scholar
29. Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med 1997;16:981–91.10.1002/(SICI)1097-0258(19970515)16:9<981::AID-SIM510>3.0.CO;2-NSearch in Google Scholar
30. Bender R, Ange S, Freitag G, Rampisch HJ. Letters to the editors. Statist Med 1998;17:945–50.Search in Google Scholar
31. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006;34:1996–2003.10.1097/01.CCM.0000226413.54364.36Search in Google Scholar
32. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210–7.10.1016/S1473-3099(07)70052-XSearch in Google Scholar
33. Jones AE, Fiechtl JF, Brown MD, Ballew JJ, Kline JA. Procalcitonin test in the diagnosis of bacteremia: a meta-analysis. Ann Emerg Med 2007;50:34–41.10.1016/j.annemergmed.2006.10.020Search in Google Scholar
34. McLean A. Procalcitonin: seeking a niche. Crit Care 2009;13:149.10.1186/cc7799Search in Google Scholar
35. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 2011;9:107.10.1186/1741-7015-9-107Search in Google Scholar
36. van Nieuwkoop C, Bonten TN, van’t Wout JW, Kuijper EJ, Groeneveld GH, Becker MJ, et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care 2010;14:R206.10.1186/cc9328Search in Google Scholar PubMed PubMed Central
37. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012;55:651–62.10.1093/cid/cis464Search in Google Scholar PubMed PubMed Central
38. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea. J Am Coll Cardiol 2010;55:2062–76.10.1016/j.jacc.2010.02.025Search in Google Scholar PubMed
39. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea. J Am Coll Cardiol 2011;58:1057–67.10.1016/j.jacc.2011.06.006Search in Google Scholar PubMed
40. Peacock WF, Nowak R, Christenson R, DiSomma S, Neath SX, Hartmann O, et al. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med 2011;18: 947–58.10.1111/j.1553-2712.2011.01150.xSearch in Google Scholar PubMed
41. Once MY, Dilmen U, Erdeve O, Ozdemir R, Calisici E, Yurttutan S, et al. Pro-adrenomedullin as a prognostic marker in neonatal sepsis. Pediatr Res 2012; DOI: 10.1038/pr.2012.106.10.1038/pr.2012.106Search in Google Scholar PubMed
42. Travaglino F, De Berardinis B, Magrini L, Bongiovanni C, Candelli M, Silveri NG, et al. Utility of procalictonin (PCT) and mid regional pro-adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in emergency department (ED). A comparison with APACHE II score. BMC Infect Dis 2012;12:184.10.1186/1471-2334-12-184Search in Google Scholar PubMed PubMed Central
43. Pezzilli R, Barassi A, Pigna A, Morselli-Labate AM, Imbrogno A, Fabbri D, et al. Time course of proadrenomedullin in the early phase of septic shock. A comparative study with other proinflammatory proteins. Panminerva Med 2012;54:211–7.Search in Google Scholar
44. Suberviola B, Castellanos-Ortega A, Llorca J, Ortiz F, Iglesias D, Prieto B. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. Swiss Med Wkly 2012;142:1–8.10.4414/smw.2012.13542Search in Google Scholar PubMed
45. Guignant C, Voirin N, Venet F, Lepape A, Monneret G. Persistent high level of circulating midregional-proadrenomedullin and increased risk of nosocomial infections after septic shock. J Trauma Acute Care Surg 2012;72:293–6.10.1097/TA.0b013e31823a0d23Search in Google Scholar PubMed
46. Hagag AA, Elmahdy HS, Ezzat AA. Prognostic value of plasma pro-adrenomedullin and antithrombin levels in neonatal sepsis. Indian Pediatr 2011;48:471–3.10.1007/s13312-011-0074-1Search in Google Scholar PubMed
©2013 by Walter de Gruyter Berlin Boston
